Damien M Cronier
Overview
Explore the profile of Damien M Cronier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
859
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villalobos V, Mo G, Agulnik M, Pollack S, Rushing D, Singh A, et al.
Cancer Med
. 2019 Dec;
9(3):882-893.
PMID: 31821732
Background: Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet-derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics...
2.
Jones R, Mo G, Baldwin J, Peterson P, Ilaria Jr R, Conti I, et al.
Cancer Chemother Pharmacol
. 2018 Nov;
83(1):191-199.
PMID: 30406840
Purpose: Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFRα. Olaratumab plus doxorubicin improved survivalversus doxorubicin in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised...
3.
Gerber D, Swanson P, Lopez-Chavez A, Wong L, Dowlati A, Pennell N, et al.
Lung Cancer
. 2017 Aug;
111:108-115.
PMID: 28838379
Background: In non-small cell lung cancer (NSCLC), platelet-derived growth factor receptor (PDGFR) mediates angiogenesis, tissue invasion, and tumor interstitial pressure. Olaratumab (IMC-3G3) is a fully human anti-PDGFRα monoclonal antibody. This...
4.
Mo G, Baldwin J, Luffer-Atlas D, Ilaria Jr R, Conti I, Heathman M, et al.
Clin Pharmacokinet
. 2017 Jun;
57(3):355-365.
PMID: 28620891
Background And Objectives: Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-α (PDGFRα). In a randomized phase II study, olaratumab plus doxorubicin met its predefined...
5.
Tate S, Sykes A, Kulanthaivel P, Chan E, Turner P, Cronier D
Clin Pharmacokinet
. 2017 May;
57(3):335-344.
PMID: 28540640
Background And Objectives: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated clinical activity in a number of different cancer types. The objectives of this study were...
6.
Raje N, Moreau P, Terpos E, Benboubker L, Grzasko N, Holstein S, et al.
Br J Haematol
. 2016 Dec;
176(5):783-795.
PMID: 28005265
In this double-blind, Phase 2 study, 220 patients with relapsed/refractory multiple myeloma were randomly assigned 1:1:1 to receive placebo (N = 72), tabalumab 100 mg (N = 74), or tabalumab...
7.
Tap W, Jones R, Van Tine B, Chmielowski B, Elias A, Adkins D, et al.
Lancet
. 2016 Jun;
388(10043):488-97.
PMID: 27291997
Background: Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue sarcoma and median overall survival for those treated is 12-16 months, but few, if any,...
8.
Raje N, Faber Jr E, Richardson P, Schiller G, Hohl R, Cohen A, et al.
Clin Cancer Res
. 2016 Jun;
22(23):5688-5695.
PMID: 27287072
Purpose: Tabalumab, a human mAb that neutralizes B-cell-activating factor (BAFF), demonstrated antitumor activity in xenograft models of multiple myeloma. Here we report on a phase I study of relapsed/refractory multiple...
9.
Patnaik A, Rosen L, Tolaney S, Tolcher A, Goldman J, Gandhi L, et al.
Cancer Discov
. 2016 May;
6(7):740-53.
PMID: 27217383
Unlabelled: We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 and 6, in a multicenter study including...
10.
Tate S, Burke T, Hartman D, Kulanthaivel P, Beckmann R, Cronier D
Br J Cancer
. 2016 Mar;
114(6):669-79.
PMID: 26978007
Background: Resistance to BRAF inhibition is a major cause of treatment failure for BRAF-mutated metastatic melanoma patients. Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, overcomes this resistance in xenograft...